(Q90609334)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

title

Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

Zachary S Buchwald

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Jason A Efstathiou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

publication date

30 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

Bladder Cancer (Amsterdam, Netherlands)

15 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

page(s)

15-27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

15 April 2020

copyright license

start time

30 April 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Clinical status and rate of recovery of blood lymphocyte levels after radiotherapy for bladder cancer

1 reference

12 December 2020

Enhancement by X-ray irradiation of target cell susceptibility to natural killer cells

1 reference

12 December 2020

Cellular immunity to human urinary bladder carcinoma. II. EEffect of surgery and preoperative irradiation

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

Immunological Surveillance in Neoplasia

1 reference

12 December 2020

Superficial bladder cancer: progression and recurrence

1 reference

12 December 2020

Selective bladder preservation by combination treatment of invasive bladder cancer

1 reference

12 December 2020

Solid cancers after bone marrow transplantation.

1 reference

12 December 2020

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.

1 reference

12 December 2020

IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

1 reference

12 December 2020

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

1 reference

12 December 2020

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

1 reference

12 December 2020

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants

1 reference

12 December 2020

Fever and cancer in perspective

1 reference

12 December 2020

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

1 reference

12 December 2020

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

1 reference

12 December 2020

Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature

1 reference

12 December 2020

Defining bacillus Calmette-Guerin refractory superficial bladder tumors

1 reference

12 December 2020

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

12 December 2020

IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS

1 reference

12 December 2020

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 reference

12 December 2020

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

1 reference

12 December 2020

Cancer after kidney transplantation in the United States

1 reference

12 December 2020

Cancer and the chemokine network

1 reference

12 December 2020

The immunobiology of cancer immunosurveillance and immunoediting

1 reference

12 December 2020

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

1 reference

12 December 2020

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

12 December 2020

P53 and prognosis: new insights and further complexity

1 reference

12 December 2020

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

1 reference

12 December 2020

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

12 December 2020

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

1 reference

12 December 2020

Management of BCG failures in superficial bladder cancer: a review

1 reference

12 December 2020

Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

1 reference

12 December 2020

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

12 December 2020

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

1 reference

12 December 2020

High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer

1 reference

12 December 2020

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder

1 reference

12 December 2020

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

12 December 2020

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

12 December 2020

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology

1 reference

12 December 2020

Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients

1 reference

12 December 2020

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

1 reference

12 December 2020

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

1 reference

12 December 2020

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

1 reference

12 December 2020

Radiation-induced bystander signalling in cancer therapy

1 reference

12 December 2020

Complications following radical cystectomy for bladder cancer in the elderly

1 reference

12 December 2020

Definition and management of patients with bladder cancer who fail BCG therapy

1 reference

12 December 2020

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

1 reference

12 December 2020

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

12 December 2020

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 December 2020

The management of BCG failure in non-muscle-invasive bladder cancer: an update

1 reference

12 December 2020

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

12 December 2020

Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

1 reference

12 December 2020

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

12 December 2020

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

1 reference

12 December 2020

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

1 reference

12 December 2020

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience

1 reference

12 December 2020

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

12 December 2020

Maximizing tumor immunity with fractionated radiation

1 reference

12 December 2020

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

12 December 2020

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

1 reference

12 December 2020

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

1 reference

12 December 2020

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin

1 reference

12 December 2020

The convergence of radiation and immunogenic cell death signaling pathways.

1 reference

12 December 2020

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

1 reference

12 December 2020

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

1 reference

12 December 2020

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

1 reference

12 December 2020

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

1 reference

12 December 2020

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

1 reference

12 December 2020

Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation

1 reference

12 December 2020

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

1 reference

12 December 2020

Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

12 December 2020

Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer

1 reference

12 December 2020

Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer

1 reference

12 December 2020

Radiation and immunotherapy: a synergistic combination.

1 reference

12 December 2020

Trimodality bladder preservation therapy for muscle-invasive bladder cancer

1 reference

12 December 2020

Mutational landscape and significance across 12 major cancer types

1 reference

12 December 2020

T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con

1 reference

12 December 2020

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

1 reference

12 December 2020

Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

1 reference

12 December 2020

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

1 reference

12 December 2020

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

12 December 2020

The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population

1 reference

12 December 2020

Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).

1 reference

12 December 2020

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

1 reference

12 December 2020

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

1 reference

12 December 2020

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial

1 reference

12 December 2020

Combinations of immunotherapy and radiation in cancer therapy.

1 reference

12 December 2020

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

1 reference

12 December 2020

Radiation therapy and immunotherapy: growing pains

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

1 reference

12 December 2020

Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 December 2020

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.

1 reference

12 December 2020

Identifiers

DOI

10.3233/BLC-150014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30561443%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

PubMed publication ID

30561443

1 reference